Significant Reduction In Glucose Levels Research Articles

Studying the Anti-microbial and Alpha Amylase Inhibition Activity of Cerium Oxide Nanoparticles for Biomedical Applications

Cerium oxide nanoparticles (CNP) have been produced using a wet chemical technique. The therapeutic capacities of cerium oxide nanoparticles are determined based on the analysis of their anti-diabetic and antibacterial activities. The study below demonstrated the antibacterial characteristics of cerium oxide nanoparticles (CNP) against several bacteria. Specifically, the inhibition zones observed for Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Enterococcus gergovae were 14.5mm, 11mm, 17mm, and 15mm, respectively. The results obtained indicate that CNP has the potential to address the urgent problem of hospital-acquired microbial infections, particularly those caused by antibiotic-resistant microorganisms. Additionally, the anti-diabetic property of CNP was evaluated and found to have a 66% alpha amylase inhibition, which suggests a significant reduction in glucose levels. Therefore, it has the potential to be utilized as an antidiabetic medication as well. The study has produced a compound with potent biological capabilities that can be enhanced through a synthesis technique and utilized in the pharmaceutical industry.

Exploring the combined therapeutic efficacy of bexarotene and icariin in type 2 diabetic rats.

The aim of this study was to determine the single and combined antidiabetic activity and side effects of the retinoid X receptor agonist bexarotene and the thioredoxin-interacting protein inhibitor and peroxisome proliferator-activated receptor γ and AMP-activated protein kinase activator icariin. The rats were grouped as healthy (control), diabetes, diabetes + bexarotene (20mg/kg), diabetes + icariin (60mg/kg), diabetes + bexarotene (10mg/kg) + icariin (30mg/kg) low-dose combination and diabetes + bexarotene (20mg/kg) + icariin (60mg/kg) high-dose combination groups. Icariin treatment led to a significant reduction in glucose levels compared with the diabetes control group, a remarkable outcome observed 45 days after the initial application. HbA1c levels of the icariin and low-dose combination treatment groups were significantly lower than in the diabetes group. Notably, icariin treatment also significantly elevated HOMA-β levels, which is indicative of improved β-cell function. Icariin significantly decreased glucose levels at 30 and 120min in the oral glucose tolerance test. Moreover, it ameliorated hepatocyte degeneration, hepatic cord dissociation, congestion, mononuclear cell infiltration in the liver, and degeneration in the pancreas. Icariin treatment exhibited robust antidiabetic effects with fewer side effects than other treatment options in this study. In future studies, long-term and varying doses of icariin will contribute to the development of novel antidiabetic drugs.

Impact of hospital-community diabetes management intervention in Central Region, Ghana: A retrospective study

ObjectiveEffective diabetes management remains suboptimal in low-resourced countries including Ghana. We determined the effectiveness of hospital-community link diabetes management intervention on glycaemic control and other outcomes. MethodsA retrospective study design, using secondary data from the Ghana-Netherlands for Health Foundation diabetes programme. The z-test was used for proportions, to compare parameters between baseline (2017) and endpoint (2022). The Friedman test was used to assess changes in blood glucose levels, and the multivariable Logistic regression to identify factors associated with blood glucose control. ResultsAnalyses of 251 clinical records showed decline in median blood glucose levels across six years from 8.8 mmol/L (7.2–12.9) in 2017 to 6.5 mmol/L (5.7–7.2) (p = 0.001) in 2022, recording 43 % increase in patients attaining glycaemic control in 2022 (p = 0.001). The Friedman test showed significant reduction in glucose levels (χ2 = 319.2, p = 0.001), with an effect size of 0.25 using the Kendall test. The logistic regression analyses revealed that patients on metformin and Glibenclamide combination were more likely to achieve glycaemic control than those on metformin monotherapy (adjusted OR = 7.30, 95 % CI 2.31–23.01, p = 0.001). ConclusionThe intervention achieved significant reduction in blood glucose levels. Patients with diabetes benefit from the hospital-community link diabetes management intervention regarding glycaemic control.

Insulin Extended Release from PLA-PEG Stereocomplex Nanoparticles.

This report addresses the challenges of controlled drug delivery for peptide and protein therapeutics by introducing a novel approach of nano formulation fabricated in aqueous media applying stereo-interaction mechanism with poly(D-lactide)-polyethylene glycol (D-PLA-PEG). To overcome the inherent poor stability of peptide and protein therapeutics, stereocomplexation of the peptide, insulin, is applied, onto D-PLA-PEG in aqueous media. Nanoparticles of ≈400nm are spontaneously formed when water-soluble D configured PLA-PEG diblock copolymer and L- configured insulin interlock into a stereocomplex, owing to their concave convex fitness. In vitro release of insulin from stereocomplex in phosphate buffer solution (PBS) pH 7.4 solution shows sustained release for 14 weeks. The therapeutic efficacy of the PLA-insulin stereocomplex nanoparticles are evaluated in diabetic Akita mice. Blood glucose levels and body weight are closely monitored for a period of 17weeks, revealing a significant reduction in glucose levels of the Akita mice treated with insulin stereocomplex, as well as normal body weight gain. These findings suggest that the stereocomplex nanoparticles of insulin-D-PLA-PEG present a promising and effective sustained and extended release platform for insulin. Notably, the use of water-soluble D-PLA-PEG for stereocomplexation in water expands the applicability of this approach to fabricate controlled delivery systems for peptide and protein therapeutics.

Intraoperative Insulin Infusion Regimen versus Insulin Bolus Regimen for Glucose Management during CABG Surgery: A Randomized Clinical Trial

Background and Aim: The stress induced by surgery disrupts the delicate balance between hepatic glucose production and glucose utilization in the body. Despite the significance of intraoperative glycaemic control for diabetic patients, limited attention has been given to this aspect. Two methods for administering insulin to manage glucose levels during surgery exist. This study aimed to compare intraoperative glucose levels in diabetic patients undergoing Coronary Artery Bypass Graft (CABG) surgery using either insulin infusion or the bolus method. Method: This was a Randomized Clinical Trial (RCT). Seventy diabetic patients aged 40 or older scheduled for CABG surgery were enrolled in the trial. They were randomly assigned, using block randomization, to receive intraoperative insulin via either infusion or the bolus method. The primary outcome measure was intraoperative glucose levels. Subsequent insulin unit requirements and intraoperative potassium levels were secondary outcomes. Data was monitored throughout the CABG procedure and recorded at six different checkpoints. Results: Male patients constituted the majority in both groups, with no significant differences in the preoperative characteristics of patients, including HbA1c levels and comorbidities. The infusion regimen demonstrated a statistically significant reduction in glucose levels (-19.12 mg/dL, 95% CI: -27.68 to -10.55, P<0.001, Cohen's d=1.06) compared to the bolus regimen. The total insulin units administered in the infusion group were 480 units, as opposed to 600 units in the bolus group (P=0.001, Cohen's d=0.85). Importantly, no cases of hypoglycemia or hyperkalemia were reported among the patients. Conclusion: Intraoperative glucose control using insulin was effective for CABG patients with diabetes. However, the infusion regimen exhibited statistically superior results compared to the bolus regimen. Clinical Trials Registry and Registration Number: The trial received approval from the Ethics Committee on 2/1/2019/2020 and was registered on Clinicaltrials.gov under ID: NCT04824586.

Inhibitory effects of Buddleja scordioides (salvilla) leaves on digestive enzymes and carbohydrate absorption in vivo

The effects of Buddleja scordioides (BsLI) leaf infusions on digestive enzymes and carbohydrate absorption were evaluated. The BsLI yield was 21.64 %. In addition, a chemical characterization was carried out identifying hydroxybenzoic acids, hydroxycinnamic acids, flavonols, flavanones and flavones. In vitro studies were performed to determine the inhibitory action of BsLI on lipase, α-amylase, and α-glucosidase. Then, in rats, oral starch tolerance tests (OSTT) were carried out using BsLI at a dose of 9.5 mg/kg body weight. Results showed moderate inhibition of lipase and α-glucosidase, but greater inhibition of α-amylase compared to positive controls. During the OSTT trial, the group receiving BsLI showed a significant reduction in glucose levels compared to the negative control group. Bioactive compounds, such as naringenin, luteolin, quercetin, and coumaric acid, were identified after BsLI administration. Furthermore, the consumption of BsLI was safe and showed antioxidant activity like Trolox. In conclusion, BsLI may have an enhanced effect on glucose metabolism by inhibiting carbohydrate absorption.
 DOI: https://doi.org/10.54167/tch.v17i2.1221

Washing-Free and Label-Free Onsite Assay for Inorganic Pyrophosphatase Activity Using a Personal Glucose Meter.

In this study, we demonstrated a personal glucose meter-based method for washing-free and label-free inorganic pyrophosphatase (PPase) detection, which relies on the cascade enzymatic reaction (CER) promoted by hexokinase and pyruvate kinase. In principle, the absence of target PPase enables adenosine triphosphate sulfurylase to catalyze the conversion of pyrophosphate (PPi) to ATP, a substrate of CER, which results in the significant reduction of glucose levels by the effective CER process. In contrast, the PPi cleavage activity works in the presence of target PPase by decomposing PPi to orthophosphate (Pi). Therefore, the CER process cannot be effectively executed, leading to the maintenance of the initial high glucose level that may be measured by a portable personal glucose meter. Based on this novel strategy, a quantitative evaluation of the PPase activity may be achieved in a dynamic linear range of 1.5-25 mU/mL with a detection limit of 1.18 mU/mL. Compared with the previous PPase detection methods, this method eliminates the demand for expensive and bulky analysis equipment as well as a complex washing step. More importantly, the diagnostic capability of this method was also successfully verified by reliably detecting PPase present in an undiluted human serum sample with an excellent recovery ratio of 100 ± 2%.

Maximal Oxygen Uptake, VO2 Max, Testing Effect on Blood Glucose Level in Adolescents with Type 1 Diabetes Mellitus.

Assessing maximal oxygen uptake (VO2 max) is generally considered safe when performed properly for most adolescents; however, for adolescents with type 1 diabetes mellitus (T1DM), monitoring glucose levels before and after exercise is critical to maintaining euglycemic ranges. Limited guidance exists for glucose level recommendations for the pediatric population; therefore, the purpose of this retrospective clinical chart review study was to determine the effects of VO2 max testing on blood glucose levels for adolescents with T1DM. A total of 22 adolescents (mean age = 15.6 ± 1.8 years; male = 13, 59.1%) with a diagnosis of T1DM participated in a Bruce protocol for VO2 max from January 2019 through February 2020. A statistically significant reduction in glucose levels between pretest (<30 min, mean = 191.1 mg/dL ± 61.2) and post-test VO2 max (<5 min, mean = 166.7 mg/dL ± 57.9); t(21) = 2.3, p < 0.05) was detected. The results from this current study can help guide health and fitness professionals in formulating glycemic management strategies in preparatory activities prior to exercise testing and during exercise testing.

Сравнение эффективности применения инозитолов и комбинированных оральных контрацептивов для коррекции метаболических, эндокринных и клинических параметров пациенток с синдромом поликистозных яичников

The use of a combination of myoinositol and D-chiroinositol in a ratio of 5:1 (MI/DCI 5:1), manganese and folic acid appears promising for the correction of androgen-dependent dermopathy, regulation of the menstrual cycle, restoration of ovulation in patients planning pregnancy, as well as for improving endocrine and metabolic parameters, carbohydrate and lipid metabolism in patients with polycystic ovary syndrome (PCOS). Objective. To compare the effects of combined oral contraceptives (COCs) and combination of MI/DCI 5:1, manganese and folic acid on endocrine, metabolic and clinical parameters in patients with PCOS. Patients and methods. A prospective open-label clinical trial included 129 patients with PCOS. Patients in group 1 (A, n = 63) were prescribed COCs with antiandrogenic activity containing ethinyl estradiol 20 μg/drospirenone 3 mg; patients in group 2 (B, n = 66) were prescribed the combination of MI/DCI 5:1, manganese and folic acid for 6 months. Lifestyle modifications were also recommended for all patients: physical activity and diet therapy. Results. Low serum androgen levels were observed in both groups. The use of COCs resulted in a more significant reduction in hirsutism according to the Ferriman-Gallwey score and clinical manifestations of acne. Administration of the combination of MI/DCI 5:1 showed good results in improving carbohydrate and lipid metabolism in patients with PCOS. Thus, in group B there was a significant reduction in glucose levels (4.9 ± 0.3 vs. 5.2 ± 0.5 mmol/L, p &lt; 0.01) and fasting insulin (12.1 ± 5.3 vs. 22.2 ± 4.9 mmol/L, p &lt; 0.01), HOMA and CARO indices. No changes in carbohydrate metabolism were observed during COCs administration, but there was an increase in cholesterol levels (6.0 ± 0.7 vs. 5.7 ± 0.5 mmol/L, p &lt; 0.05), low-density lipoproteins (LDL) (3.9 ± 0.4 vs. 3.5 ± 0.6 mmol/L, p &lt; 0.05), and atherogenic coefficient (AC). Lipid profile parameters in group B improved significantly from baseline by reducing cholesterol (5.1 ± 0.6 vs. 5.6 ± 0.6 mmol/L, p &lt; 0.05), triglycerides (1.5 ± 0.4 vs. 1.8 ± 0.3 mmol/L, p &lt; 0.05), and LDL (2.7 ± 0.5 vs. 3.6 ± 0.8 mmol/L, p &lt; 0.01). Diet therapy and administration of the combination of MI/DCI 5:1, manganese and folic acid resulted in a 4.4% decrease in waist circumference and a 4.8% decrease in body mass index (BMI). In contrast, the COCs group showed a 2.1% increase in waist circumference and a 4.7% increase in BMI, which may be related to an increased appetite. In group B, the regularity of menstrual cycle in patients with PCOS was also analyzed. After 6 months of therapy, a regular cycle was observed in 40% of patients vs. 11% of patients at baseline with a mean duration of 33.3 ± 9.4 days (p &lt; 0.05). Conclusion. Lifestyle modification with the combination of MI/DCI 5:1, manganese and folic acid is effective for the correction of endocrine, metabolic, and clinical profile in patients with PCOS and appears to be a promising new alternative to COCs regardless of reproductive planning. Key words: polycystic ovary syndrome, myoinositol, D-chiroinositol, hyperandrogenism, insulin resistance, hirsutism, acne

492-P: Glucose Level Recommendations for Vo2 Max Exercise Testing in Adolescents with Type 1 Diabetes

Glucose level recommendations have yet to be established for adolescents diagnosed with type 1 diabetes (T1D) who participate in VO2 max exercise testing for clinical or strength and conditioning purposes. Although a decrease in glucose may be expected throughout, and immediately after exercise testing, a minimal pre-test glucose setpoint has not been established to reduce the risk of hypoglycemia. Retrospective medical and sports medicine chart reviews were conducted of clinical pediatric sports medicine and physical activity program patients with a diagnosis of T1D (N = 24; mean age = 15.5 ± 1.7 years; male = 14, 58.3%) who participated in a modified Bruce protocol for maximal oxygen uptake (VO2 max). The majority of the participants identified as non-Hispanic (n = 22, 91.7%) and white (n = 19, 79.2%). Their average body mass index (BMI) based on age and sex was in the 66th percentile ± 19.5 and their average hemoglobin A1c (HbA1c) was 8.8% ± 1.8. Almost 2/3 of the participants (n = 15, 62.5%) wore a continuous glucose monitor. Their average VO2 max peak was 43.7 ml/kg/min ± 7.1. A paired-samples t-test was employed to detect a statistically significant reduction in glucose levels between pretest (&amp;lt; 30 minutes, mean = 191.1 mg/dl ± 61.2) and post-test VO2 max (&amp;lt; 5 minutes, mean = 166.7 mg/dl ± 57.9); t(21) = 2.3, p &amp;lt;. 05). The American Diabetes Association recommends that glucose levels do not fall below 70 mg/dl in order to prevent symptoms of hypoglycemia. These results demonstrated a mean decrease in glucose of 24.4 mg/dl and provide further data which can be used to set safety parameters and expectations for adolescents with T1D participating in VO2 max testing. Disclosure K. King: None. B. J. Thrasher: None. T. E. Mckay: None. K. A. Wintergerst: None.

Study the effect of herbal mixture plants extract on blood sugar level in normal and experimentally diabetic mice

The use of medicinal plants for the management of diabetes mellitus is an old practice that has become even more relevant in a modern perspective. The present work was designed to evaluate the effect of a mixture of three medicinal plants which used in folk medicine in Iraq, These plants are (Aloe vera, Artemisia herba alba, and Teucrium polium) on the levels of blood glucose in normal and alloxan-induced diabetic mice, The aqueous extract of the herbal mixture was prepared and chemical detection of phenols, flavonoids, tannins, terpenes, steroids, glycosides, and saponins was carried out. Results revealed that the aqueous extract contains phenols, flavonoids, tannins, terpenes, glycosides, and saponins compounds. Evaluations of the parameters of our study were carried out on both standard and alloxan-induced diabetic mice. Thirty male mice were randomly divided into six equal groups: Group I (control): was kept as control negative mice treated with only distilled water. Group II: normal mice treated with aqueous extract of an herbal mixture at a dose (500 mg/kg/day).Group III: normal mice treated with aqueous extract of an herbal blend at a dose (250 mg/kg/day). The other 3 groups were subcutaneously administered a single dose (100 mg/kg) of alloxan to induce experimental diabetes. Groups IV (Diabetic): was kept as control positive, alloxan-induced diabetic mice treated with only distilled water. Groups V: alloxan-induced diabetic mice treated with aqueous extract of an herbal mixture at a dose (500 mg/kg/day). Group VI: alloxan-induced diabetic mice treated with aqueous extract of an herbal blend at a dose (250 mg/kg/day), respectively, for ten days. Results showed that normal mice treated with aqueous extract has no significant change in body weights and blood glucose level except those treated with a high dose of aqueous extract since they exhibited a significant decrease (P ≤ 0.05) in blood glucose level. The results indicated a significant reduction in glucose level in diabetic mice after treatment with a high dose of aqueous extract of the herbal mixture. In conclusion, our results support that the aqueous extract of these plant exhibits anti-diabetic as compared with each plant alone, where we tested each of these plants in previous studies.

Comparison of ethanol yield from pretreated lignocellulo-starch biomass under fed-batch SHF or SSF modes

The ethanol yields from lignocellulo-starch biomass (peels of sweet potato, elephant foot yam, tannia, greater yam and beet root) by fed-batch separate hydrolysis and fermentation (F-SHF) and simultaneous saccharification and fermentation (F-SSF) using Saccharomyces cerevisiae were compared. Fed-batch saccharification of steam or dilute sulphuric acid pretreated biomass enhanced the reducing sugar yield which resulted in high RS consumption, volumetric ethanol productivity and ethanol yield during the first 24 h fermentation under F-SHF mode, while continuous production and utilization of reducing sugars occurred up to 72 h in F-SSF. Dilute sulphuric acid pretreated residues under F-SHF gave higher ethanol yield (34–43 g/L) and productivity (274–346 ml/kg dry biomass) than steam pretreatment (27–36 g/L and 223–295 ml/kg respectively), while F-SSF was superior for steam pretreated peels of sweet potato, elephant foot yam and tannia giving ethanol yields from 281 to 302 ml/kg. Glucose and xylose were present in all the hydrolysates with a preponderance of glucose and fermentation resulted in significant reduction in glucose levels in both F-SHF and F-SSF. Higher levels of total soluble phenolics and hydroxymethyl furfural were observed in the hydrolysates from dilute sulphuric acid pretreatment and yeast assimilated/detoxified part of the inhibitors, while only trivial amounts of furfural were present due to the low xylose content in the hydrolysates. Continuous formation led to higher accumulation of inhibitors in F-SSF despite supplementation with the detoxification mix comprising Tween 20, polyethylene glycol and sodium borohydride. F-SHF of dilute sulphuric acid pretreated biomass could be considered as a comparatively advantageous process where only one time feeding of enzyme cocktail and yeast was adopted compared to multiple feeds of enzymes and yeast along with other additives such as detoxification mix or nutrient solution in F-SSF.

Synthesis of some novel orsellinates and lecanoric acid related depsides as α-glucosidase inhibitors

Sixteen novel orsellinic esters (6a-l, 7a-d) along with four lecanoric acid related depsides (3a-c, 4) were synthesized and confirmed their structures by spectroscopic data (1H, 13C & HRMS). The synthesized compounds were evaluated for their in vitro α-glucosidase (Saccharomyces cerevisiae) inhibitory potential. Among the tested compounds, 3c (IC50: 140.9 μM) and 6c (IC50: 203.9 μM) displayed potent α-glucosidase inhibitory activity and found more active than the standard drug acarbose (IC50: 686.6 μM). Both the test compounds were subjected to in vivo antihyperglycemic activity using sucrose loaded model in Wistar rats and found compound 3c exhibited significant reduction in glucose levels.

Glucose level evaluation in monopedicled rectus abdominis myocutaneous flap after venous occlusion: experimental study in rats.

to validate an experimental model for the measurement of glycemic levels in surgical flaps with the use of common glucometers, and to analyze the diagnostic criteria for hypoperfusion of such flaps. we performed vertical myocutaneous rectus abdominis flaps with upper pedicles bilaterally in 20 male Wistar rats, divided into two groups: with and without venous occlusion of the pedicle. We measured glucose levels in the flaps and in the systemic circulation with standard glucometers. We tested the accuracy of alternative diagnostic criteria for the detection of hypoperfusion. from 15 minutes of venous occlusion on, there was a significant reduction in glucose levels measured in the congested flap (p<0.001). Using a minimum difference of 20mg/dl in the glycemic levels between the flap and systemic blood, 30 minutes after occlusion, as a diagnostic criterion, the sensitivity was 100% (95% CI 83.99-100%) and specificity of 90% (95% CI 69.90-97.21%) for the diagnosis of flap congestion. It is possible to measure glucose levels in vertical myocutaneous rectus abdominis flaps of Wistar rats, perfused or congested, using a common glucometer. The diagnostic criteria that compare the glucose levels in the flaps with the systemic ones were more accurate in the evaluation of tissue perfusion.

Antihyperglycemic and Antilipidemic Effects of the Ethanol Extract Mixture of Ligularia fischeri and Momordica charantia in Type II Diabetes-Mimicking Mice.

The extract of the Momordica charantia fruit (MCE) is recognized as an alternative treatment for diabetes. The extract of Ligularia fischeri leaves (LFE) is traditionally used as a folk medicine for treating inflammatory diseases in Korea as well. In this study, we investigated the synergistic effect of MCE combined with LFE on antihyperglycemic and antihyperlipidemic potentials. Based on the α-glucosidase inhibitory effect and promotion of adipocyte differentiation in the 3T3-L1 cell line, the MLM was prepared with MCE:LFE (8:2 weight:weight). MLM showed the synergistic effects in the promotion of the glucose uptake rate, suppression of dipeptidyl peptidase-4 (DPP-4) mRNA expression, upregulation of an insulin receptor substrate and glucose transporter type-4 expression, and an increase in insulin-associated signaling in C2C12 cells. In addition, the efficacy of peroxisome proliferator-activated receptor-γ agonism and glucose uptake rate by MLM supplementation was significantly enhanced in vitro. Then, the antihyperglycemic and antihyperlipidemic effects of MCE, LFE, and MLM at the dose of 50, 100, and 200 mg/kg/day (n = 6 per each group) were determined in streptozotocin (STZ)-insulted mice fed an atherogenic diet (ATH) for 4 weeks. In addition, MLM (50, 100, and 200 mg/kg/day, n = 5 per each group) was supplemented in ATH-fed db/db mice for 10 weeks. Compared with MCE or LFE alone, MLM supplementation led to a more significant reduction of glucose levels in both STZ/ATH and db/db/ATH mice as well as lowered lipid profiles in STZ/ATH mice. In addition, the stimulation of islet of Langerhans regeneration was more pronounced by MLM supplementation in both mice models. In conclusion, antihyperglycemic and antihyperlipidemic effects were strengthened by the combined extracts of L. fischeri and M. charantia (MLM) in diabetes-mimicking mice.

Preparation and Antidiabetic Effect of Orally Administered Nifedipine‐Loaded Solid Lipid Nanoparticles in Fructose-Induced Diabetic Rats

The use of Nifedipine (NI), a dihydropyridine calcium channel blocker, is limited due to its poor aqueous solubility. However, NI loaded solid-lipid nanoparticles (NI-SLN) are known to exhibit suitable pharmacokinetic properties and good biocompatibility. The present investigation was designed to evaluate the effects of NI-SLN on glucose homeostasis, lipid metabolism and liver function in fructose-induced diabetic rats. NI-SLN was prepared by high pressure homogenization technique followed by lyophilization with trehalose as cryoprotectant. Diabetes was induced into rats by the administration of fructose (10%) in drinking water for six weeks. After induction of diabetes, rats were divided into four groups for the oral ingestion of NI, NI-SLN and/or vehicles and their effects on blood glucose levels, oral glucose tolerance test (OGTT), lipid profile, biochemical parameters, electrolytes and histopathology were observed. Single dose administration and treatment with NI-SLN showed significant glucose lowering efficacy in fructose-induced diabetic rats. Although NI and NI-SLN did not alter the fasting blood glucose level in normal rats, diabetic rats treated with NI-SLN resulted in significant reduction in glucose level for 24 hr. In OGTT, NI-SLN exhibited significant antihyperglycemic activity in both normal and diabetic rats. So, NI-SLN has better glucose lowering efficacy than that of pure NI in diabetic rats. The survival rates in rats among the treatment groups were 100%. Treatment with NI-SLN significantly improved lipid profiles than NI alone and the effect was dose-dependent. Administration of NI-SLN significantly reduced uric acid, creatinine levels and maintained a good cationic balance. After two weeks of NI-SLN treatment, hepatocytes regained their normal architecture, and the beneficial effect could be correlated with the reduction of SGOT and total bilirubin levels. Therefore, NI-SLN was found to be useful for the enhancement of bioavailability and exhibited profound antidiabetic activity in rats. The results of the study suggested that NI-SLN exerted better improvement in glucose levels, lipid profiles and organ protection than pure NI and might have some beneficial effects in the management of diabetic patients.

The Effect of Nigella Sativa Extract (Thymoquinone) on Glucose Insulin Levels and Body Weight of Induced Diabetic Female Rats

<i>Background</i>: Diabetes is one of the most common chronic diseases in the world. It characterized by hyperglycemia resulting from defects in insulin secretion or action or both. Chronic complications of diabetes such as cardiovascular damage, cataracts and retinopathy, nephropathy and polyneuropathy. Induction of experimental diabetes in rodentsis used by Streptozotocin (STZ). A number of therapeutic effects including the effect on diabetes have been described for the Nigella sativa extract (Thymoquinone). <i>Aim:</i> The goal of this study to investigate the effect of Nigella sativa extract (Thymoquinone) as a herbal medicines on female induced diabetic rat, and hence investigating the comparison of changes in body weight, levels of glucose and insulin in serum, between normal and diabetic rats. <i>Methods:</i> Adult female Wister rats, weighing 200–250 g, were used. Rats were divided into four groups normal control (Group A), experimental control group (Group B) rats were given 0.5 ml of the single sodium-citrate buffer injection and 1ml of Sesame oil orally via gavage. (Group C) treated STZ-diabetic (60 mg/kg B. W., IP), with of low Nigella sativa extract (Thymoquinone) (5 mg/kg B. W, IP), and (Group D) treated STZ-diabetic (60 mg/kg B. W., IP), with of high Nigella sativa extract (Thymoquinone) (10 mg/kg B. W., IP) and until the end of experiment were evaluated to assess its effect on body weight, glucose and insulin levels in different groups. <i>Results:</i> The results indicated that significant reduction in glucose levels of high dose of treated group with Nigella sativa extract (Thymoquinone) (10 mg/kg b. w.) compared to low dose. Both dose of treated group with <i>Nigella sativa</i> extract (Thymoquinone) (5 and 10 mg/kg b. w.) very high significantly (p &lt; 0.001) reduced in body weight and insulin levels in comparison to both group normal control and experimental control groups. Moreover, there was no significant difference observed in body weight between normal control and experimental control groups. The present findings suggest an antidiabetic effect of Nigella sativa extract (Thymoquinone) may attributed through a decrease in hepatic gluconeogenesis. <i>Conclusions:</i> Thymoquinone has the ability to improve oxidative stress in plasma and tissues of STZ induced diabetic rats as evidenced by improved glycemic. Thus, Thymoquinone could be considered as a treatment strategy for diabetic complications.

Influence of Grand Multiparity on the Levels of Insulin, Glucose and HOMA-IR in Comparison with Nulliparity and Primiparity.

It is to compare the levels of fasting glucose and insulin as well as insulin resistance in grand multiparas with primiparity and nulliparity. Fasting blood samples were collected from 100 non-pregnant ladies as control group, 100 primiparity pregnant women and 100 grand multiparity pregnant women. Glucose (FBS) and insulin (FSI) concentrations were measured by Hitachi 912 full automated Chemistry Analyzer (Roche Diagnostics, Germany) as manufacturer procedure. Insulin resistance was calculated following the formula: FBG (mg dL-1)×FSI (μU mL-1)/405. This study found a significant reduction in glucose level in primiparity when compared to control group but it was increased significantly in multiparity comparing to primiparity and control. Insulin level showed significant high concentrations in pregnant women and increased significantly in grand multiparas comparing to primiparas and controls. As a result of that, HOMA-IR was increased significantly by increasing of parity. Also, there was a significant increase in fasting insulin and a decrease in insulin sensitivity with parity with association to age and obesity. Grand multiparity is associated with an increased risk of subsequent clinical insulin resistance (HOMA-IR).

Efficacy of Aqueous Extract of Helicteres isora on Glucose Level in Type-2 Diabetic Patients Practicing Yoga. A Cohort Study

Background: Diabetes mellitus patients thrive very hard to reduce their glucose levels by using various hypoglycemic agents. Many hypoglycemic agents cause side effects and fail to reduce glucose level, when they use for a long time. Folklore natural medicines will successfully act on many diseases without causing any side effects when it was consumes prolonged. Patients practicing yoga and exercise with the traditional medicines contribute a significant efficacy in management of diabetes in very short period. Main Observations: We report the cases of 40 to 60 year old type-2 diabetic patients were evaluated for the efficacy of Helicteres isora concoction 5 mg/5 ml concentration with practicing yoga and exercise. The patients were observed for the glucose levels and body weight before evaluating with cohort study. The results from the cohort study showed that the group 1M and 1O had significant reduction in glucose levels when compared to control groups treated for four weeks. Conclusions: Type-2 Diabetic Patients administered orally with H.isora concoction in practicing yoga reveals that they were significantly reduced in blood glucose levels and body weight. Thus the study provides a novel hypoglycemic agent which is very cheaper that ails to the management of diabetes mellitus.

Association Between Hormone Replacement Therapy and Glycemic Control in Postmenopausal Women with Type 2 Diabetes

Abstract Introduction. In women with diabetes, the changes that accompany menopause may further diminish glycemic control. Little is known about how hormone replacement therapy (HRT) affects glucose metabolism in diabetes. The aim of this study was to examine whether HbA1C levels are influenced by current HRT among postmenopausal women with type 2 diabetes. Methods. A total of 40 postmenopausal women with type 2 diabetes were enrolled. All of them fulfilled the criteria of natural menopause, with intact uterus, low estrogen levels (E2) and high follicle-stimulating hormone (FSH) levels. Half of them (20 women) were assigned to take HRT (DM-HRT group). The other half (20 women) were assigned to the control group, those who did not take HRT (DM-non HRT group). HRT consisted of 17 β-estradiol (E2) 1 mg and drospirenone (DRSP) 2 mg. Fasting plasma glycemia, insulinemia and HbA1C were followed in both groups throughout 12 months. Results. The mean age was 49 years (SD±3,3) and 48,5 (SD±3.1), respectively. HRT was associated with statistically significant decrease in serum fasting glucose, HbA1C and insulinemia levels in the DM-HRT group. There was no significant reduction in glucose levels and HbA1C together with no significant increase in insulinemia levels in the DM non-HRT group throughout 12 months. Conclusion. HRT was associated with statistically significant decrease of plasma glucose levels and HbA1C level. Larger clinical trials are necessary to understand whether HRT may improve glycemic control in women with diabetes, especially when it is given shortly after entering menopause.